These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 18055006)

  • 21. Usefulness of computed tomography in predicting cytoreductive surgical outcomes for ovarian cancer.
    Fujwara K; Yoshino K; Enomoto T; Fujita M; Ueda Y; Miyatake T; Kimura T; Muraji M; Fujita H; Kimura T; Hori M
    Arch Gynecol Obstet; 2011 Dec; 284(6):1501-7. PubMed ID: 21347681
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preoperative PET/CT score can predict incomplete resection after debulking surgery for advanced serous ovarian cancer better than CT score, MTV, tumor markers and hematological markers.
    Wang J; Liu L; Pang H; Liu L; Jing X; Li Y
    Acta Obstet Gynecol Scand; 2022 Nov; 101(11):1315-1327. PubMed ID: 35979992
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radiological predictors of cytoreductive outcomes in patients with advanced ovarian cancer.
    Borley J; Wilhelm-Benartzi C; Yazbek J; Williamson R; Bharwani N; Stewart V; Carson I; Hird E; McIndoe A; Farthing A; Blagden S; Ghaem-Maghami S
    BJOG; 2015 May; 122(6):843-849. PubMed ID: 25132394
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of F18-FDG PET/CT in predicting secondary optimal de-bulking in patients with recurrent ovarian cancer.
    Amit A; Hodes A; Lavie O; Keidar Z; Matanes E; Lowenstein L
    Surg Oncol; 2017 Dec; 26(4):347-351. PubMed ID: 29113651
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictors of suboptimal surgical cytoreduction in women treated with initial cytoreductive surgery for advanced stage epithelial ovarian cancer.
    Everett EN; Heuser CC; Pastore LM; Anderson WA; Rice LW; Irvin WP; Taylor PT
    Am J Obstet Gynecol; 2005 Aug; 193(2):568-74; discussion 574-6. PubMed ID: 16098898
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CT-Based Fagotti Scoring System for Non-Invasive Prediction of Cytoreduction Surgery Outcome in Patients with Advanced Ovarian Cancer.
    Kim NY; Jung DC; Lee JY; Han KH; Oh YT
    Korean J Radiol; 2021 Sep; 22(9):1481-1489. PubMed ID: 34132077
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A multicenter validation of computerized tomography models as predictors of non- optimal primary cytoreduction of advanced epithelial ovarian cancer.
    Gemer O; Gdalevich M; Ravid M; Piura B; Rabinovich A; Gasper T; Khashper A; Voldarsky M; Linov L; Ben Shachar I; Anteby EY; Lavie O
    Eur J Surg Oncol; 2009 Oct; 35(10):1109-12. PubMed ID: 19329270
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnosis and staging of primary ovarian cancer: correlation between PET/CT, Doppler US, and CT or MRI.
    Nam EJ; Yun MJ; Oh YT; Kim JW; Kim JH; Kim S; Jung YW; Kim SW; Kim YT
    Gynecol Oncol; 2010 Mar; 116(3):389-94. PubMed ID: 19926121
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography.
    Bristow RE; Duska LR; Lambrou NC; Fishman EK; O'Neill MJ; Trimble EL; Montz FJ
    Cancer; 2000 Oct; 89(7):1532-40. PubMed ID: 11013368
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma.
    Nelson BE; Rosenfield AT; Schwartz PE
    J Clin Oncol; 1993 Jan; 11(1):166-72. PubMed ID: 8418230
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of optimal cytoreduction rates in emergency versus non-emergency admissions for advanced ovarian cancer: a multi-institutional study.
    Mangili G; Scambia G; Ottolina J; Fanfani F; Viganò R; Costantini B; Candiani M; Fagotti A
    Eur J Surg Oncol; 2013 Aug; 39(8):906-11. PubMed ID: 23755990
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Complete surgical cytoreduction of advanced ovarian carcinoma using the argon beam coagulator.
    Bristow RE; Montz FJ
    Gynecol Oncol; 2001 Oct; 83(1):39-48. PubMed ID: 11585412
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study.
    Eisenkop SM; Friedman RL; Wang HJ
    Gynecol Oncol; 1998 May; 69(2):103-8. PubMed ID: 9600815
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of FDG PET-CT in asymptomatic epithelial ovarian cancer with rising serum CA-125: a pilot study.
    Ghosh J; Thulkar S; Kumar R; Malhotra A; Kumar A; Kumar L
    Natl Med J India; 2013; 26(6):327-31. PubMed ID: 25073988
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: correlation with transvaginal ultrasonography, computed tomography, and histology.
    Castellucci P; Perrone AM; Picchio M; Ghi T; Farsad M; Nanni C; Messa C; Meriggiola MC; Pelusi G; Al-Nahhas A; Rubello D; Fazio F; Fanti S
    Nucl Med Commun; 2007 Aug; 28(8):589-95. PubMed ID: 17625380
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma.
    Chi DS; Venkatraman ES; Masson V; Hoskins WJ
    Gynecol Oncol; 2000 May; 77(2):227-31. PubMed ID: 10785469
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT.
    Bristow RE; del Carmen MG; Pannu HK; Cohade C; Zahurak ML; Fishman EK; Wahl RL; Montz FJ
    Gynecol Oncol; 2003 Sep; 90(3):519-28. PubMed ID: 13678719
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of 18F-FDG PET/CT in diagnosing peritoneal carcinomatosis in the restaging of patient with ovarian cancer as compared to contrast enhanced CT and tumor marker Ca-125.
    Rubini G; Altini C; Notaristefano A; Merenda N; Rubini D; Ianora AA; Asabella AN
    Rev Esp Med Nucl Imagen Mol; 2014; 33(1):22-7. PubMed ID: 23948509
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapy.
    Yan TD; Haveric N; Carmignani CP; Chang D; Sugarbaker PH
    Cancer; 2005 Feb; 103(4):839-49. PubMed ID: 15637690
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.